DK3511319T3 - Hæmmere af lysinspecifik demethylase-1 - Google Patents

Hæmmere af lysinspecifik demethylase-1 Download PDF

Info

Publication number
DK3511319T3
DK3511319T3 DK19156976.3T DK19156976T DK3511319T3 DK 3511319 T3 DK3511319 T3 DK 3511319T3 DK 19156976 T DK19156976 T DK 19156976T DK 3511319 T3 DK3511319 T3 DK 3511319T3
Authority
DK
Denmark
Prior art keywords
lysine
inhibitors
specific demethylase
demethylase
specific
Prior art date
Application number
DK19156976.3T
Other languages
Danish (da)
English (en)
Inventor
Young K Chen
Toufike Kanouni
Zhe Nie
Jeffrey Alan Stafford
James Marvin Veal
Original Assignee
Celgene Quanticel Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Res Inc filed Critical Celgene Quanticel Res Inc
Application granted granted Critical
Publication of DK3511319T3 publication Critical patent/DK3511319T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polyamides (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK19156976.3T 2014-07-03 2015-06-29 Hæmmere af lysinspecifik demethylase-1 DK3511319T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462020886P 2014-07-03 2014-07-03
EP15814038.4A EP3164380B1 (en) 2014-07-03 2015-06-29 Inhibitors of lysine specific demethylase-1

Publications (1)

Publication Number Publication Date
DK3511319T3 true DK3511319T3 (da) 2023-07-31

Family

ID=55019883

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19156976.3T DK3511319T3 (da) 2014-07-03 2015-06-29 Hæmmere af lysinspecifik demethylase-1
DK15814038.4T DK3164380T3 (da) 2014-07-03 2015-06-29 Hæmmere af lysinspecifik demethylase-1

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK15814038.4T DK3164380T3 (da) 2014-07-03 2015-06-29 Hæmmere af lysinspecifik demethylase-1

Country Status (29)

Country Link
US (3) US9902719B2 (OSRAM)
EP (2) EP3511319B1 (OSRAM)
JP (2) JP6663866B2 (OSRAM)
KR (1) KR102475498B1 (OSRAM)
CN (2) CN106795103B (OSRAM)
AU (1) AU2015284383B2 (OSRAM)
BR (1) BR112017000043A2 (OSRAM)
CA (1) CA2954049A1 (OSRAM)
CL (1) CL2016003422A1 (OSRAM)
CO (1) CO2017000549A2 (OSRAM)
CY (1) CY1125127T1 (OSRAM)
DK (2) DK3511319T3 (OSRAM)
EA (2) EA201891526A3 (OSRAM)
EC (1) ECSP17006821A (OSRAM)
ES (2) ES2907676T3 (OSRAM)
FI (1) FI3511319T3 (OSRAM)
HR (2) HRP20220414T1 (OSRAM)
HU (2) HUE058852T2 (OSRAM)
IL (2) IL249881B (OSRAM)
LT (2) LT3511319T (OSRAM)
MX (2) MX395534B (OSRAM)
PL (2) PL3511319T3 (OSRAM)
PT (2) PT3511319T (OSRAM)
RS (2) RS64423B1 (OSRAM)
SA (1) SA517380651B1 (OSRAM)
SG (2) SG11201610975RA (OSRAM)
SI (2) SI3511319T1 (OSRAM)
SM (2) SMT202300205T1 (OSRAM)
WO (1) WO2016003917A1 (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201911989SA (en) 2015-06-12 2020-02-27 Oryzon Genomics Sa Biomarkers associated with lsd1 inhibitors and uses thereof
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
CN109195593A (zh) 2016-03-15 2019-01-11 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
ES3042059T3 (en) 2016-03-16 2025-11-18 Oryzon Genomics Sa Methods to determine kdm1a target engagement and chemoprobes useful therefor
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US20190256930A1 (en) 2016-11-03 2019-08-22 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
DK3661510T3 (da) 2017-08-03 2025-01-02 Oryzon Genomics Sa Fremgangsmåder til behandling af adfærdsændringer
MX2021001608A (es) * 2018-08-10 2021-07-15 Navire Pharma Inc Inhibidores de ptpn11.
US12479845B2 (en) 2019-02-01 2025-11-25 Hanmi Pharm. Co., Ltd. Imidazopyridine derivative compounds and use of same
EP3907225A4 (en) * 2019-02-01 2022-09-14 Hanmi Pharm. Co., Ltd. COMPOUNDS DERIVED FROM IMIDAZOPYRIDINE AND THEIR USE
EP3941465B1 (en) 2019-03-20 2025-09-17 Oryzon Genomics, S.A. Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
CN121370879A (zh) 2019-03-20 2026-01-23 奥莱松基因组股份有限公司 治疗边缘型人格障碍的方法
WO2021004610A1 (en) 2019-07-05 2021-01-14 Oryzon Genomics, S.A. Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors
US11360505B2 (en) 2020-02-11 2022-06-14 Simmonds Precision Products, Inc. Distributed network time synchronization
CN114105950B (zh) * 2020-08-31 2022-09-06 南京明德新药研发有限公司 吡唑类化合物及其应用
TWI834127B (zh) * 2021-03-11 2024-03-01 大陸商南京明德新藥研發有限公司 噻吩類化合物及其應用
US20240216357A1 (en) * 2021-03-24 2024-07-04 Sichuan Huiyu Pharmaceutical Co., Ltd. Polycyclic compound and application thereof
BR112023020554A2 (pt) 2021-04-08 2023-12-05 Oryzon Genomics Sa Combinações de inibidores de lsd1 para o tratamento de cânceres mieloides
CN116102533A (zh) * 2021-11-11 2023-05-12 中国科学院上海药物研究所 一种芳杂环类化合物及其应用
CN119497613A (zh) 2022-05-09 2025-02-21 奥莱松基因组股份有限公司 使用lsd1抑制剂治疗nf1-突变肿瘤的方法
JP2025516647A (ja) 2022-05-09 2025-05-30 オリゾン・ゲノミクス・ソシエダッド・アノニマ Lsd1阻害薬を用いる悪性末梢神経鞘腫(mpnst)の治療法
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1963188A1 (de) * 1969-12-17 1971-06-24 Bayer Ag Neue Cyanphenyl-1,4-dihydropyridinderivate
AU2002214546A1 (en) * 2000-09-29 2002-04-08 Cor Therapeutics, Inc. Bicyclic pyrimidin-4-one based inhibitors of factor xa
US7365069B2 (en) * 2002-04-10 2008-04-29 Bexel Pharmaceuticals Inc. Pyrimidone derivatives
JP2005170792A (ja) * 2002-11-22 2005-06-30 Mitsubishi Pharma Corp L−プロリン誘導体およびその医薬としての用途。
CA2548918C (en) * 2003-12-11 2013-05-21 Mitsubishi Pharma Corporation Alpha-amino acid derivatives and use thereof as medicines
WO2006073167A1 (ja) * 2005-01-07 2006-07-13 Ono Pharmaceutical Co., Ltd. ピロリジン誘導体
PL372332A1 (pl) * 2005-01-19 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego
WO2006129181A2 (en) * 2005-06-03 2006-12-07 Orchid Research Laboratories Limited Preparation of 4-pyrimidone derivatives for treating inflammatory diseases
AU2006287202B2 (en) * 2005-09-01 2013-01-24 Eli Lilly And Company 6-arylalkylamino- 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2c receptor agonists
JP2007197324A (ja) * 2006-01-23 2007-08-09 Toray Ind Inc 2,4,5−置換−1,3−アゾール誘導体
WO2008021309A1 (en) 2006-08-15 2008-02-21 Wyeth Imidazolidin-2-one derivatives useful as pr modulators
TW200815428A (en) * 2006-08-15 2008-04-01 Wyeth Corp Oxazolidone derivatives as PR modulators
PE20081803A1 (es) 2007-03-09 2008-12-11 Wyeth Corp Sintesis y caracterizacion de la forma ii polimorfica de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il)tiazol-4-il)benzonitrilo
CL2008002793A1 (es) * 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
WO2009132310A1 (en) * 2008-04-25 2009-10-29 Wisconsin Alumni Research Foundation Inhibitors of udp-galactopyranose mutase thwart mycobacterial growth
US20130096160A1 (en) * 2010-04-14 2013-04-18 Secretary, Department Of Health And Human Services Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production
WO2012009475A1 (en) * 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
WO2013132380A1 (en) * 2012-03-06 2013-09-12 Lupin Limited Thiazole derivatives as alpha 7 nachr modulators
SMT202300014T1 (it) * 2013-12-11 2023-05-12 Celgene Quanticel Research Inc Inibitori della demetilasi lisina-specifica-1
RU2016136091A (ru) * 2014-02-14 2018-03-19 Дзе Юниверсити Оф Бритиш Коламбиа Соединения, воздействующие на днк-связывающий домен (dbd) андрогенового рецептора человека, в качестве терапевтических средств, а также способы их применения
AU2015253040B2 (en) * 2014-05-01 2020-04-09 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
FR3020945B1 (fr) 2014-05-16 2016-05-06 Oreal Composition pour colorer les fibres keratiniques comprenant une base d'oxydation et un coupleur heteroaryle particulier
HUE050564T2 (hu) * 2014-06-27 2020-12-28 Celgene Quanticel Res Inc Lizinspecifikus demetiláz-1 inhibitorai
SG11201700007YA (en) * 2014-07-03 2017-01-27 Celgene Quanticel Res Inc Inhibitors of lysine specific demethylase-1

Also Published As

Publication number Publication date
KR102475498B1 (ko) 2022-12-07
JP2019108346A (ja) 2019-07-04
MX395534B (es) 2025-03-25
EA201891526A2 (ru) 2018-12-28
IL272130A (en) 2020-03-31
US9902719B2 (en) 2018-02-27
SG10201802501RA (en) 2018-05-30
US20180127408A1 (en) 2018-05-10
JP2017525668A (ja) 2017-09-07
EA201891526A3 (ru) 2019-05-31
AU2015284383A1 (en) 2017-02-02
CN108530424A (zh) 2018-09-14
MX2017000168A (es) 2017-05-01
EA033698B1 (ru) 2019-11-18
JP6663866B2 (ja) 2020-03-13
EP3511319B1 (en) 2023-05-03
LT3511319T (lt) 2023-08-25
CN106795103A (zh) 2017-05-31
MX2020010900A (es) 2022-09-13
SG11201610975RA (en) 2017-01-27
JP6768857B2 (ja) 2020-10-14
SA517380651B1 (ar) 2020-09-30
MX376207B (es) 2025-03-07
RS64423B1 (sr) 2023-09-29
CN108530424B (zh) 2021-10-01
EP3511319A1 (en) 2019-07-17
ECSP17006821A (es) 2017-03-31
DK3164380T3 (da) 2022-03-28
IL249881B (en) 2020-01-30
BR112017000043A2 (pt) 2018-07-17
CO2017000549A2 (es) 2017-04-20
US20190002456A1 (en) 2019-01-03
IL249881A0 (en) 2017-03-30
PL3164380T3 (pl) 2022-04-04
EP3164380A1 (en) 2017-05-10
PT3511319T (pt) 2023-06-29
US20170129882A1 (en) 2017-05-11
IL272130B (en) 2021-03-25
SMT202300205T1 (it) 2023-09-06
ES2907676T3 (es) 2022-04-26
PL3511319T3 (pl) 2023-09-11
WO2016003917A1 (en) 2016-01-07
ES2948782T3 (es) 2023-09-19
PT3164380T (pt) 2022-03-02
EA201790085A1 (ru) 2017-08-31
FI3511319T3 (fi) 2023-07-20
US10100046B2 (en) 2018-10-16
AU2015284383B2 (en) 2019-04-18
HRP20230595T1 (hr) 2023-09-15
SI3164380T1 (sl) 2022-06-30
CN106795103B (zh) 2019-07-12
EP3164380B1 (en) 2022-02-09
HRP20220414T1 (hr) 2022-05-27
CA2954049A1 (en) 2016-01-07
RS63074B1 (sr) 2022-04-29
SI3511319T1 (sl) 2023-10-30
CY1125127T1 (el) 2024-02-16
LT3164380T (lt) 2022-06-27
EP3164380A4 (en) 2018-07-18
SMT202200136T1 (it) 2022-05-12
KR20170018100A (ko) 2017-02-15
HUE062558T2 (hu) 2023-11-28
HUE058852T2 (hu) 2022-09-28
CL2016003422A1 (es) 2017-11-10

Similar Documents

Publication Publication Date Title
IL263586B (en) Inhibitors of the menin-mll interaction
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3511319T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3371171T3 (da) Inhibitorer af RET
LT3137169T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
DK3512850T3 (da) Inhibitorer af menin-mll-interaktionen
DK3080100T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3851537T3 (da) Behandling af hyperbilirubinæmi
LT3303334T (lt) Tirozinkinazės inhibitoriai
HUE042335T2 (hu) ROR-gamma dihidropirrolopiridin inhibitorai
DK3317400T3 (da) Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter
BR112017000042A2 (pt) inibidores de desmetilase-1 lisina-específica
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DK3132009T3 (da) Fremgangsmåde
DK3283210T3 (da) Fremgangsmåde
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
DK3204352T3 (da) Hæmmere af lysin-gingipain
DK3418273T3 (da) Derivater af flavagliner
DK3137449T3 (da) Fremgangsmåder til fremstilling af substituerede cycloseriner
DK3511000T3 (da) Krystallinsk form x2 af grapiprant
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
IL254502A0 (en) Solid forms of menaquinols
DK2910535T3 (da) Sammensætning til anvendelse af ekspanderet perlit